Our team is dedicated to finding and telling you more about the products and deals we love. If you love them too and decide to purchase through the links below, we may receive a commission. Pricing and availability are subject to change.
Our team is dedicated to finding and telling you more about the products and deals we love. If you love them too and decide to purchase through the links below, we may receive a commission. Pricing and availability are subject to change.
Intel has laid out a plan to help automakers dealing with the global semiconductor shortage that has left companies like GM canceling production shifts.
You're going to want to share this story with all your friends.
Franklin Resources, Inc. (Franklin Templeton) (NYSE: BEN) today reported preliminary month-end assets under management of $1,498.9 billion at March 31, 2021, compared to $1,500.5 billion at February 28, 2021. This month’s AUM reflected slightly positive market gains offset by long-term net outflows, primarily driven by a single fixed income institutional redemption of nearly $6 billion that had minimal impact on revenue.
SANTA PAULA, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Calavo Growers, Inc. (“Calavo”) (“Company”) (Nasdaq-GS: CVGW), a global leader in the avocado and value-added fresh food industries, today reminded shareholders that due to continued public health concerns related to the spread of COVID-19, the Company will provide its shareholders with the capability to attend its 2021 annual shareholder meeting virtually. The meeting will consist only of the formal business portion and the Company is offering the virtual alternative as a way for shareholders to have essentially the same meeting experience without attending in person. The annual meeting will be held at 1:00 pm Pacific Time on April 21, 2021. Holders of record at the close of business on February 22, 2021 will be entitled to participate, submit questions and vote at the annual meeting by following the instructions available on the virtual meeting website at www.virtualshareholdermeeting.com/CVGW2021 and using the 16-digit control number included in their proxy materials. Non-shareholders may attend the annual meeting as a guest but will not have the option to vote any shares or ask questions during the virtual meeting. Cumulative VotingNote that cumulative voting for directors will not be allowed via the live webcast. Shareholders who wish to vote cumulatively for directors should provide proxy instructions before the Annual Meeting at www.proxyvote.com. Shareholders will be able to vote cumulatively for directors in person at the Annual Meeting, but there will be no difference in the tallying of cumulative votes for directors provided through instructing a proxy in advance at www.proxyvote.com compared to voting in person at the Annual Meeting. Shareholders need not attend the Annual Meeting in person simply to vote cumulatively for directors. Whether or not a shareholder plans to access the live call or webcast of the Annual Meeting, the Company urges all shareholders to vote and submit their proxies in advance of the Annual Meeting using one of the methods described in its proxy materials. Shareholders are encouraged to read the Company’s proxy statement carefully. All information included in the proxy statement remains unchanged except with respect to the matters set forth herein. About Calavo Growers, Inc. Calavo Growers, Inc. is a global avocado-industry leader and provider of value-added fresh food serving retail grocery, foodservice, club stores, mass merchandisers, food distributors and wholesalers worldwide. The Company’s Fresh segment procures and markets fresh avocados and select other fresh produce, including tomatoes and papayas. The Renaissance Food Group (RFG) segment creates, markets and distributes a portfolio of healthy, fresh foods, including fresh-cut fruit, fresh-cut vegetables and prepared foods. The Foods segment manufactures and distributes guacamole and salsa. Founded in 1924, Calavo’s fresh food products are sold under the respected Calavo brand name as well as Garden Highway, Chef Essentials and several private label and store brands. Contact: Financial Profiles, Inc.Lisa Mueller, Senior Vice President(310) firstname.lastname@example.org This communication may be deemed to be solicitation material in respect of the 2021 annual meeting of shareholders (the “Annual Meeting”) of Calavo Growers, Inc., a California corporation (the “Company”). On March 1, 2021, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the “Commission”) in connection with the Annual Meeting. SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER SOLICITING MATERIALS THAT ARE FILED WITH THE COMMISSION WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS TO BE VOTED UPON. The Company’s proxy statement and any other solicitation materials filed by the Company with the Commission can be obtained free of charge at the Commission’s website at www.sec.gov and at the investor relations section of the Company’s website at ir.calavo.com. Shareholders may also write to the Company at the following email address to request copies of these materials: email@example.com. The Company, its directors and certain of its officers will be participants in the solicitation of proxies from shareholders in respect of the Annual Meeting. Detailed information regarding the identity of participants, and their respective interests in the Company by security holdings or otherwise, are set forth in the definitive proxy statement for the Annual Meeting. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.
A few years ago, while covering a story on Republican New Hampshire legislator Werner Horn, I summoned the best and brightest scholars that America had to offer. Horn, who represents his 95.9 percent white hometown in his state’s House of Representatives, confounded people who actually know things by stating that “owning slaves doesn’t make you racist.” During an interview with The Root, Horn doubled down by insisting that the Founding Fathers were not racist.
HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported SimpliciT-1 Study will be presented at A Scientific Symposium: In celebration of the 100th anniversary of the University of Toronto’s discovery of insulin (Insulin100) held virtually, April 15 & 16, 2021. The presentation titled “The SimpliciT-1 Study: Hepatoselective Glucokinase Activation Via TTP399 For The Treatment Of Type 1 Diabetes Mellitus" was awarded first place in the symposium’s Post Doc - Clinical Category and earned the opportunity to be presented to the world’s leading experts on type 1 diabetes. Dr. Klara Klein, MD, PhD, Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill, and Sub-Principal Investigator of the SimpliciT-1 study, will present the data in a 15 minute presentation on April 15th in a session held from 1:10-1:25pm ET. Registration is available here. The Insulin100 symposium, chaired by Dr. Daniel Drucker of the University of Toronto, celebrates the 100th anniversary of the life-saving discovery of insulin and aims to provide comprehensive updates on the latest advances in diabetes treatment and management. “We are pleased that vTv’s research in type 1 diabetes is being recognized by the diabetes community,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “We are dedicated to advancing TTP399 and believe that it has the potential to be a new treatment option for type 1 diabetes that improves patients’ lives.” vTv is currently conducting a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes and is planning a pivotal trial that will be initiated later this year. About the SimpliciT-1 Study The SimpliciT-1 Study was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D. The Phase 2 study was conducted in two parts under a treat-to-target protocol to evaluate the safety and efficacy of TTP399 in T1D patients over 12 weeks of daily dosing following a multi-week insulin optimization and placebo run-in period. Results from the study showed that treatment with 800mg of TTP399 demonstrated statistically significant reductions in HbA1c, as previously announced. Importantly, it also resulted in a clinically relevant (~40%) reduction in the frequency of severe or symptomatic hypoglycemia, as compared to placebo. TTP399 exhibited a favorable safety profile, with abnormal serum and urine ketones detected less frequently in participants in the TTP399 group than in the placebo group. These data suggest the potential of TTP399 to lower HbA1c and reduce hypoglycemia without increasing the risk of ketosis and should be further evaluated as an adjunctive therapy for the treatment of type 1 diabetes. About vTv TherapeuticsvTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics. Forward-Looking StatementsThis release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements. Contacts Investors: Corey DavisLifeSci AdvisorsCDavis@LifeSciAdvisors.comorMedia: PR@vtvtherapeutics.com Source: vTv Therapeutics Inc.
The "High Purity Solvents: Global Markets" report has been added to ResearchAndMarkets.com's offering.
PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 April 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021. Tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in mUM. The OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine). Treatment-related adverse events were manageable and consistent with the proposed mechanism. “This is the first investigational therapy to demonstrate improved OS in metastatic uveal melanoma,” said Bahija Jallal, Chief Executive Officer of Immunocore. “We believe these data demonstrate that tebentafusp has the potential to provide a meaningful difference in the treatment of metastatic uveal melanoma, a highly aggressive disease for which there is no effective standard of care.” In a separate oral presentation on Monday April 12, Marcus O. Butler shared an analysis of previously treated uveal melanoma patients who had prolonged survival. Two posters from the phase 2 IMCgp100-102 study are also available for on-demand viewing at the AACR website. These analyses investigated the proposed mechanism of action (MoA), including inducing an increase in cytokines and T cell trafficking into the tumor. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the U.S. Food and Drug Administration (FDA) and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. Immunocore will be working with the FDA to complete submission of a BLA for tebentafusp in the third quarter of 2021. The Company will host a conference call for industry, health and investment professionals on Tuesday, April 13th at 7:30 am ET to discuss the phase 3 IMCgp100-202 trial. The webcast can be accessed directly through this link. A replay of the webcast will be made available shortly after the conclusion of the call and archived on the Investor Relations section of the Company’s website for at least 90 days. PLENARY AND ORAL PRESENTATIONS Title: Phase 3 randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma Date and Time: Plenary session presentation (CT002), Saturday April 10th at 11:30am - 1:30pm ETPresenter: Jessica C. Hassel (PI), University Hospital Heidelberg, Heidelberg, GermanyAbstract #: 5342Session Title: Phase III Clinical Trials Title: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival Date and Time: Oral presentation (CT038), Monday April 12th at 1:30pm – 3:15pm ETPresenter: Marcus O. Butler (PI), Princess Margaret Cancer Centre, Toronto, ON, CanadaAbstract #: 5338Session Title: Disease-Oriented Innovative Clinical Research and Trials POSTER PRESENTATIONS Title: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells Poster #: 517Presenter: Marcus O. Butler (PI) Title: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp Poster #: 1673Presenter: Jessica Hassel (PI) ## About Immunocore Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. About ImmTAC® Molecules Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognise and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumours, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumours, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumours. About Tebentafusp Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392). About Uveal Melanoma Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Metastatic uveal melanoma typically has a poor prognosis and has no currently accepted optimal management or treatment. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases per year in the United States). Up to 50% of people with uveal melanoma will eventually develop metastatic disease. When the cancer spreads beyond the eye, only approximately half of patients will survive for one year. Forward Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but are not limited to, statements regarding the efficacy, safety and therapeutic potential of tebentafusp, the design, progress, timing, scope and results of the Company’s clinical trials including IMCgp100-202, the anticipated timing of disclosure of results of clinical trials, plans for initiating future clinical trials and extension studies, the progress of the Company’s development programs including tebentafusp, the potential benefit of Breakthrough Therapy Designation or Orphan Drug Designation for tebentafusp, the timing of regulatory filings including estimates regarding the planned submission a BLA for tebentafusp, the likelihood of obtaining regulatory approval of any of the Company’s product candidates including tebentafusp, and the regulatory approval path for tebentafusp. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and the uncertainties and timing of the regulatory approval process. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 25, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information except as required by law. CONTACT: Immunocore Debra Nielsen, Head of CommunicationsT: +1 (610) 368-8602E: firstname.lastname@example.org Follow on Twitter: @Immunocore Consilium Strategic Communications (corporate and financial)Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji/Jessica HodgsonT: +44 (0)203 709 5700E: Immunocore@consilium-comms.com Investor Relations Clayton Robertson, Head of Investor RelationsT: +1 215-384-4781E: email@example.com
PHILADELPHIA, PA, April 12, 2021 (GLOBE NEWSWIRE) -- FTAC Athena Acquisition Corp. (NASDAQ:FTAAU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more technology and financial services technology companies, today announced that the holders of the Company’s units may elect to separately trade the Class A ordinary shares and warrants underlying the units commencing on April 16, 2021. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol “FTAAU” and the Class A ordinary shares and warrants are expected to trade under the symbols “FTAA” and “FTAAW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Cantor Fitzgerald & Co. served as the sole book-running manager for the offering. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on February 22, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 5th Floor, New York, New York 10022, email: firstname.lastname@example.org. Copies of the registration statement can be accessed for free through the SEC's website at www.sec.gov. This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law. Contact Information: Amanda Abrams email@example.com (215) 701-9693
All amounts in Canadian dollars unless otherwise stated. BROOKFIELD NEWS, April 12, 2021 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX: BAM.A, NYSE: BAM) announced today that it has exercised its right to redeem its C$600,000,000 principal amount of 4.54% Notes due March 31, 2023 (the “Notes”) on May 13, 2021.The redemption price for the Notes will be determined in accordance with the provisions of the trust indenture dated September 20, 1995 and the seventeenth supplemental indenture dated September 12, 2012 and will include accrued and unpaid interest on the Notes up to, but not including, the redemption date. Notice of redemption has been sent today to CDS Clearing and Depository Services Inc. (“CDS”), and the trustee, Computershare Trust Company of Canada. Non-registered holders (banks, brokerage firms or other financial institutions) who maintain their interests in the Notes through CDS should contact their CDS customer service representative with any questions about the redemption. Brookfield Asset Management Inc. is a leading global alternative asset manager with US$600 billion of assets under management across real estate, infrastructure, renewable power, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alternative investment products to investors around the world—including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors. Brookfield Asset Management is listed on the New York and Toronto stock exchanges under the symbols BAM and BAM.A, respectively. For more information, please contact: Communications & Media:Claire HollandTel: (416) 369-8236Email: firstname.lastname@example.orgInvestor RelationsLinda Northwood Tel: (416) 359-8647 Email: email@example.com
Timely and convenient access to vaccinations is critical, now and in the futureTEMPE, Ariz., April 12, 2021 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company engaged in the design and manufacture of the Invisalign system, iTero intraoral scanners, and exocad CAD/CAM services for orthodontic and restorative dentistry, today announced its support to expand access to vaccinations by U.S. dentists. As seen over the last year, managing health care resources during a pandemic or other health crisis is a complex mix of preparation and execution, with access to responsible care being a key consideration. Federal, state, and local public health officials and health care providers have worked to balance access to COVID-19 testing and healthcare while also meeting other health needs – both routine and unexpected – that continue even during a pandemic. As the number of people vaccinated against COVID-19 increases across the U.S., it is important to review and build on lessons learned in order to optimize responsiveness for future events. One of those lessons is the potential value of using networks of existing, trusted, community-level health care providers when rolling out vaccination plans. “Since the start of the pandemic, Align’s customers – primarily dentists and orthodontists across the country – have been at the forefront of their profession and healthcare, in general, using social media and virtual appointment and treatment monitoring tools to stay connected with and communicate public health and safety protocols to their patients,” said Julie Coletti, Align Technology senior vice president, chief legal and regulatory officer. “As essential health care providers of ongoing health care services, they have earned their patients’ trust by staying current with the latest health and safety protocols and public health requirements to safely and responsibly treat their patients.” As trusted, highly qualified health care professionals, dentists can expand the number of care providers that offer immunizations. According to the American Dental Association, 9 percent of Americans (31 million people) see a dentist every year, but do not see a physician1. This is a significant statistic to be considered as part of any future plans for vaccine administration. Dentists Provide Experienced Care Before completing dental school and becoming licensed, dentists are professionally trained to administer intraoral and extraoral injections into nerve tissue for local anesthesia – which is arguably more difficult to effectively administer than a vaccine injected into the shoulder muscle. Further, many states permit dentists to administer dermal fillers, Botox® injections, and to start IVs for procedures requiring sedation. Building on Pandemic Policies A majority of states have established the foundation for dentist-provided vaccinations by affirmatively permitting dentists to administer COVID-19 vaccinations. On March 16, 2021, the U.S. Department of Health and Human Services amended an emergency declaration under the Public Readiness and Emergency Preparedness Act to authorize additional providers, including dentists and dental students, to vaccinate patients for COVID-19 nationwide regardless of state laws that prevent dentists from doing so.3 Align believes that these recent pandemic-related policies should be the start of additional integration of dentists to vaccinate against other diseases. For example, augmenting the role of the dental profession in routine immunization of oral health related diseases such as Human Papillomavirus (HPV) would increase society’s access to future immunizations.2 Such steps would establish a more robust vaccine program by expanding access at a community level through trusted and competent dentists. 1 ADA Health Policy Institute, “Could Dentists Relieve Physician Shortages, Manage Chronic Disease?”, David Leader, D.M.D., M.P.H.; Marko Vujicic, Ph.D.; Brittany Harrison, M.A.; http://www.ada.org/~/media/ADA/Science%20and%20Research/HPI/Files/HPIBrief_1218_1.pdf 2 North Carolina Oral Health Collaborative (NCOHC), “Dentists’ Role in Vaccination: An Opportunity for Public Health Impact”, Zachary Brian, DMD, MHA, https://oralhealthnc.org/dentists-role-in-vaccination-an-opportunity-for-public-health-impact/ 3 https://www.federalregister.gov/documents/2021/03/16/2021-05401/seventh-amendment-to-declaration-under-the-public-readiness-and-emergency-preparedness-act-for About Align Technology, Inc.Align Technology designs, manufactures and offers the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and exocad CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 200 thousand doctor customers, and is key to accessing Align’s 500 million consumer market opportunity worldwide. Align has helped doctors treat over 9.6 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information. For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero systems and services, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com. Align TechnologyMadelyn Homick408firstname.lastname@example.orgZeno GroupSarah Johnson828email@example.com
MIND Technology, Inc. (NASDAQ: MIND) ("MIND" or the "Company") today announced financial results for its fiscal 2021 fourth quarter and year ended January 31, 2021.
Laureate Education, Inc. (NASDAQ: LAUR) plans to release results for the quarter ended March 31, 2021, on Thursday, May 6, 2021, before the stock market opens. Following the release, the Company will host a telephone conference call with investors and analysts at 8:30 a.m. ET to discuss the first quarter results and the Company's business outlook.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights03/31/202143,039,18049,104,029 About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. TALEN® is a registered trademark owned by Cellectis. For further information, please contact: Media contacts:Pascalyne Wilson, Communications Manager, +33776991433, firstname.lastname@example.org IR contact:Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, email@example.com Attachment Voting_Rights_PR_March_EN_docx
MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer will present at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 10:30 a.m. ET. The live webcast will be available at https://wsw.com/webcast/bloomburton6/thtx/. The live and archived webcast link will also be available in the ‘News’ section of the Company’s website. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov For media inquiries:Denis BoucherVice-President, Communications and Corporate Affairs514-336-7800 For investor inquiries:Leah GibsonSenior Director, Investor Relationsir@theratech.com617-356-1009
Danaos Corporation (the "Company") (NYSE: DAC) announced today the consummation of its previously announced $1.25 billion refinancing of a substantial majority of its outstanding senior secured indebtedness. On April 12, 2021, the Company refinanced all of the outstanding indebtedness, which aggregated $1.3 billion as of December 31, 2020, under nine of the Company’s senior secured credit facilities, with the proceeds from a $815 million senior secured credit facility with Citibank N.A. and National Westminster Bank plc who have been lenders to the Company for more than 30 years, a $135 million sale leaseback agreement with Oriental Fleet International Company Limited, an affiliate of COSCO Shipping Lease Co., Ltd., with respect to five vessels, and the net proceeds of the Company’s February 2021 offering of $300 million of 8.500% Senior Secured Notes due 2028.
NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Mercer International (NASDAQ: MERC) will release its first quarter results for the period ended March 31, 2021 on Thursday, April 29, 2021, after the close of the market. David M. Gandossi, President and Chief Executive Officer and David K. Ure, Senior Vice President Finance, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, April 30, 2021, at 10:00 am ET to discuss the results. The call can be accessed by dialing one of the following: North America: (888) 241-0326International: (647) 427-3411Conference ID: 1957695 Listeners can also access the conference call live over the Internet by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/wt6dyuct A recording of the completed conference call can be accessed for fifteen days through a link on the Company's home page at http://www.mercerint.com, or by dialing (855) 859-2056 and entering Conference ID 1957695. Please allow 15 minutes prior to the call to visit the site and download and install any necessary audio software. For additional information on accessing the call, please contact Daniela Navarria of Mercer International at firstname.lastname@example.org or (604) 639-4602. At Mercer International Inc., we are exceptional people creating bioproducts for a more sustainable world. We are a diversified global producer of forest products, bioproducts, and green electricity with operations in Germany, Canada, and Australia with a consolidated annual production capacity of approximately 2.2 million tonnes of kraft pulp and 550 million board feet of softwood lumber. For further information, please visit www.mercerint.com. APPROVED BY: David M. Gandossi, FCPA, FCA President & CEO604-684-1099 David K. Ure, CPA, CGASenior VP Finance, CFO & Secretary604-684-1099
SunCoke Energy, Inc. (NYSE: SXC), the largest independent producer of high-quality coke in the Americas, published its second annual Sustainability Report.
‘Was it an accident or intentional?’ asks president, confirming he saw ‘fairly graphic’ footage of incident
Aberdeen Income Credit Strategies Fund (NYSE: ACP) (the "Fund"), a closed-end fund, announced today that it will pay a distribution of US $0.10 per share on April 30, 2021 to all shareholders of record as of April 23, 2021 (ex-dividend date April 22, 2021). As announced on September 10, 2020, the Fund reduced its monthly distribution from $0.12 per share to $0.10 per share.